Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 24,936 shares of the biopharmaceutical company’s stock, valued at approximately $572,000. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.05% of Xencor as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Xencor by 77.7% during the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after buying an additional 2,924,510 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Xencor by 5.6% during the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after buying an additional 90,094 shares during the last quarter. State Street Corp grew its holdings in shares of Xencor by 11.1% during the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after buying an additional 110,474 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Xencor by 6.6% during the second quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after buying an additional 30,715 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of Xencor by 1.9% during the second quarter. Teachers Advisors LLC now owns 330,042 shares of the biopharmaceutical company’s stock worth $6,967,000 after buying an additional 6,260 shares during the last quarter. Institutional investors and hedge funds own 77.61% of the company’s stock.

In other Xencor news, major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder John S. Stafford III acquired 3,400 shares of the stock in a transaction on Wednesday, November 8th. The stock was acquired at an average cost of $19.89 per share, for a total transaction of $67,626.00. The disclosure for this purchase can be found here. Insiders acquired a total of 263,105 shares of company stock worth $5,206,858 in the last ninety days. 4.03% of the stock is owned by corporate insiders.

A number of research firms recently issued reports on XNCR. Cantor Fitzgerald began coverage on Xencor in a report on Wednesday. They set an “overweight” rating and a $33.00 price target on the stock. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. ValuEngine lowered Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 price target on Xencor and gave the stock a “buy” rating in a report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Xencor presently has an average rating of “Hold” and an average target price of $30.80.

Shares of Xencor, Inc. (XNCR) opened at $21.49 on Friday. Xencor, Inc. has a twelve month low of $18.55 and a twelve month high of $29.38.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/12/02/24936-shares-in-xencor-inc-xncr-purchased-by-los-angeles-capital-management-equity-research-inc.html.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.